AdvaMed May Pursue WTO Input If Japanese Trade Issues Go Unresolved
This article was originally published in The Gray Sheet
Executive Summary
AdvaMed concerns over Japanese foreign reference pricing rules and other matters could be brought before the World Trade Organization if not resolved through ongoing bilateral discussions
You may also be interested in...
Japan Reforms Failed To Sate U.S. Firms In 2002; EU Reuse Drive Ebbs, Wanes
AdvaMed will capitalize on new Exec. VP-Global Strategy & Analysis Marjory Searing's rapport with Japan Ministry of Health, Labor & Welfare officials to renew its assault on foreign reference pricing in 2003
Japan Reforms Failed To Sate U.S. Firms In 2002; EU Reuse Drive Ebbs, Wanes
AdvaMed will capitalize on new Exec. VP-Global Strategy & Analysis Marjory Searing's rapport with Japan Ministry of Health, Labor & Welfare officials to renew its assault on foreign reference pricing in 2003
Foreign reference pricing
AdvaMed leadership will meet with Japanese officials directly before and after a U.S. Trade Representative meeting in Tokyo the week of Jan. 21. AdvaMed President Pamela Bailey will visit Japan the week of Jan. 14 to discuss trade barriers for medical technologies; Executive VP-Global Strategy & Analysis Edward Rozynski will follow the USTR-Japan meeting with a visit the week of Jan. 28. The trade group backed a letter from Sens. Max Baucus (D-Mont.) and Charles Grassley (R-Iowa) to Prime Minister Junichiro Koizumi, expressing "serious concern" over a Dec. 12, 2001 policy change by the Ministry of Health, Labor and Welfare regarding the adoption of foreign reference pricing rules (1"The Gray Sheet" Dec. 24, 2001, p. 30). Co-signed by Senate leaders Tom Daschle (D-S.D.) and Trent Lott (R-Miss.), the Dec. 20 letter claims the MHLW decision "does not reflect a method that is open, transparent or in accord with free trade principles"...